144 related articles for article (PubMed ID: 28943920)
1. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
Nakashoji A; Matsui A; Nagayama A; Iwata Y; Sasahara M; Murata Y
Oncol Lett; 2017 Oct; 14(4):4135-4141. PubMed ID: 28943920
[TBL] [Abstract][Full Text] [Related]
2. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy.
Wasserman JK; Williams PA; Islam S; Robertson SJ
Pathol Res Pract; 2016 Jun; 212(6):539-44. PubMed ID: 27067807
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - single hospital experience.
Sivina E; Blumberga L; Purkalne G; Irmejs A
Hered Cancer Clin Pract; 2023 Mar; 21(1):4. PubMed ID: 36922883
[TBL] [Abstract][Full Text] [Related]
7. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
8. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
9. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
[TBL] [Abstract][Full Text] [Related]
11. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
12. Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast Carcinoma.
Riba LA; Russell T; Alapati A; Davis RB; James TA
J Surg Res; 2019 Jan; 233():436-443. PubMed ID: 30502283
[TBL] [Abstract][Full Text] [Related]
13. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
14. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.
Liu YX; Zhang KJ; Tang LL
Oncol Lett; 2018 Jun; 15(6):10008-10016. PubMed ID: 29844843
[TBL] [Abstract][Full Text] [Related]
16. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
17. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
18. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
Luangdilok S; Samarnthai N; Korphaisarn K
J Breast Cancer; 2014 Dec; 17(4):376-85. PubMed ID: 25548587
[TBL] [Abstract][Full Text] [Related]
19. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
20. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]